Ballentine Partners, LLC Pro Qr Therapeutics N.V. Transaction History
Ballentine Partners, LLC
- $5.81 Billion
- Q4 2024
A detailed history of Ballentine Partners, LLC transactions in Pro Qr Therapeutics N.V. stock. As of the latest transaction made, Ballentine Partners, LLC holds 23,035 shares of PRQR stock, worth $49,755. This represents 0.0% of its overall portfolio holdings.
Number of Shares
23,035Holding current value
$49,755% of portfolio
0.0%Shares
1 transactions
Others Institutions Holding PRQR
# of Institutions
54Shares Held
17.4MCall Options Held
37.7KPut Options Held
21.3K-
Privium Fund Management B.V.5.63MShares$12.2 Million2.56% of portfolio
-
Adage Capital Partners Gp, L.L.C. Boston, MA3.63MShares$7.83 Million0.01% of portfolio
-
Eco R1 Capital, LLC San Francisco, CA1.84MShares$3.97 Million0.14% of portfolio
-
M28 Capital Management LP Stamford, CT1.02MShares$2.2 Million1.76% of portfolio
-
Dafna Capital Management LLC Los Angeles, CA906KShares$1.96 Million0.42% of portfolio
About ProQR Therapeutics N.V.
- Ticker PRQR
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 71,362,096
- Market Cap $154M
- Description
- ProQR Therapeutics N.V., a biopharmaceutical company, engages in the discovery and development of RNA-based therapeutics for the treatment of genetic disorders. It primarily develops sepofarsen that is in phase II/III clinical trial illuminate trial for treating leber congenital amaurosis 10 disease; and ultevursen, which is in phase II/III clin...